Atossa Genetics (ATOS) Anounces Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study
Tweet Send to a Friend
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has received the second positive interim review on its Phase 1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
